PT-141 Bremelanotide Research Guide | Signal Labs
PT-141 (Bremelanotide) is an FDA-approved cyclic heptapeptide MC4R agonist studied for central melanocortin system pharmacology and sexual desire neuroscience research.
PT-141 (Bremelanotide) Research: MC4R Agonism and CNS Melanocortin Pharmacology
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from MT-2 through removal of the C-terminal hydroxyl group, converting the alcohol to the free carboxylic acid form. It activates MC1R, MC3R, and MC4R, with its primary pharmacological interest in MC4R-mediated central nervous system signalling. PT-141 achieved FDA approval in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few research peptides to complete the full clinical development pathway.
Structural Features: The Cyclic Lactam
PT-141's cyclic structure is created by a lactam bond between the Asp2 side chain carboxyl and the Lys7 side chain amino group, forming a constrained ring incorporating residues 2-7. This cyclisation is critical for receptor activity: the ring conformation positions the His-D-Phe-Arg-Trp pharmacophore in the optimal geometry for MC4R binding.
Linear heptapeptides with the same sequence but without the lactam bridge show substantially reduced MC4R affinity, confirming that the conformational constraint provided by the ring is pharmacologically essential rather than merely a stability modification.
MC4R Pharmacology
MC4R is a Gs-coupled GPCR expressed predominantly in the CNS — hypothalamic paraventricular nucleus, arcuate nucleus, brainstem, and cortical regions — rather than in peripheral melanocytes. This central expression pattern is what makes PT-141 pharmacologically distinct from MC1R-preferring MT-1.
MC4R activation in the hypothalamus influences:
- Energy homeostasis via melanocortin tone on AgRP/NPY and POMC/CART neurons
- Autonomic nervous system outflow
- Dopaminergic circuits in the mesolimbic system
- Nitric oxide production in spinal and supraspinal circuits
The last two — dopamine and nitric oxide modulation — are the proposed mechanisms underlying the sexual desire effects studied in PT-141 clinical trials. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally by increasing genital blood flow, PT-141's mechanism is entirely central — it initiates desire signalling in hypothalamic circuits rather than facilitating the physiological response in peripheral tissue.
CNS Penetration
PT-141's ability to enter the CNS is better than that of larger linear melanocortin peptides. The cyclic structure reduces molecular surface area, and the compact 7-residue ring is small enough to cross the blood-brain barrier with reasonable efficiency. Published pharmacokinetic data from clinical studies reports CNS activity within 45 minutes of subcutaneous administration.
Comparison with MT-1 and MT-2
| Property | MT-1 | MT-2 | PT-141 |
|---|---|---|---|
| Structure | Linear 13aa | Cyclic 7aa | Cyclic 7aa |
| MW | 1646.85 g/mol | 1024.18 g/mol | 1025.18 g/mol |
| Primary MCR | MC1R | MC1R-MC5R | MC3R + MC4R |
| CNS penetration | Low | Moderate | High |
| Peripheral effects | Melanogenesis | Melanogenesis + CNS | Primarily CNS |
| Clinical status | Afamelanotide (EPP) | Research only | Vyleesi (HSDD) |
FDA Approval Data
The FDA approval of Bremelanotide (PT-141) as Vyleesi in 2019 provides an unusually rich dataset for a peptide that is also used as a research compound. Published Phase 3 trial data (Clayton et al., 2016; Kingsberg et al., 2019) characterised pharmacokinetics, receptor pharmacology, and clinical endpoints, providing validated reference data for laboratory research using PT-141 as a tool compound.
Published Research References
Published Research References
For laboratory and analytical research purposes only. Not for human or veterinary use.
Related research peptides: MT-1 (Melanotan I) | MT-2 (Melanotan II) | Kisspeptin-10
View PT-141 product and buy →
MC4R in CNS Energy Circuits
Beyond its role in sexual function research, MC4R is a critical node in hypothalamic energy homeostasis circuits — providing research context for PT-141's CNS pharmacology that extends beyond its primary sexual desire research application.
MC4R-expressing neurons in the hypothalamic paraventricular nucleus (PVN) receive input from arcuate nucleus POMC neurons (releasing alpha-MSH, an MC4R agonist) and AgRP neurons (releasing AgRP, an MC4R antagonist). This antagonistic regulation creates a balance: POMC activation drives anorexia and increased energy expenditure through MC4R; AgRP activation drives appetite and decreased energy expenditure by blocking MC4R.
PT-141's high MC4R affinity connects it to this energy circuit research. Published research has examined whether PT-141 at MC4R-activating concentrations influences hypothalamic energy circuit neurophysiology — particularly PVN neuron electrophysiology and downstream autonomic outflow. For sexual desire research, the relevant MC4R circuits are in mesolimbic dopamine areas and hypothalamic centres distinct from the PVN anorexigenic circuit — though both circuit types express MC4R.
Bremelanotide FDA Approval: Research Implications
The FDA's June 2019 approval of Bremelanotide (PT-141) as Vyleesi for HSDD in premenopausal women provides a regulatory milestone that differentiates PT-141 from most research peptides. The Phase 3 clinical data (RECONNECT trial) characterised PT-141's pharmacology, safety, and efficacy under controlled clinical conditions, providing published reference standards.
Key published pharmacological parameters from the clinical data: subcutaneous bioavailability approximately 70-80%, peak plasma concentration at 1 hour, plasma half-life approximately 2.7 hours, no significant CYP enzyme interactions, and CNS penetration confirmed by central pharmacological effects. These parameters contextualise laboratory research: in vitro incubation times of 1-4 hours bracket the timeframe of peak plasma exposure in clinical use, and receptor concentrations in binding assays can be referenced to the published clinical exposure range.
Frequently Asked Questions
What distinguishes PT-141's mechanism from PDE5 inhibitors like sildenafil for research purposes?
PDE5 inhibitors (sildenafil, tadalafil, vardenafil) work peripherally: they block cGMP degradation in penile smooth muscle, maintaining NO-mediated smooth muscle relaxation that increases blood flow. This peripheral vascular mechanism requires pre-existing sexual arousal to generate the NO signal that PDE5 inhibitors then amplify. PT-141 works centrally at brain MC4R — it activates the desire and arousal circuitry in the CNS rather than facilitating the physiological response in peripheral tissue. This mechanistic distinction makes PT-141 research particularly relevant for understanding central melanocortin contributions to sexual neuroscience, while PDE5 inhibitor research addresses peripheral vascular pharmacology.
What cell lines and models are appropriate for PT-141 MC4R research?
HEK293 cells stably expressing human MC4R are the most widely used recombinant system. Functional readouts include cAMP accumulation (Gs pathway, using HTRF or AlphaScreen cAMP kits), beta-arrestin recruitment (biased agonism assessment using BRET-based assays with beta-arrestin2-YFP), and receptor internalisation (using MC4R-GFP and confocal imaging or ELISA-based surface receptor quantification). For neuronal MC4R research, hypothalamic slice electrophysiology examining PVN neuron firing rates and hypothalamic organoid models expressing endogenous MC4R provide more physiologically relevant systems.
Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide
PT-141 Stability and Reconstitution Notes
PT-141 (Bremelanotide) is a cyclic peptide with the Asp2-Lys7 lactam bridge that provides structural rigidity and protease resistance. This cyclic structure is stable under typical research conditions but should be handled appropriately:
Aqueous stability: PT-141 in aqueous solution at neutral pH is stable for several weeks at 4°C. The lactam bridge is not susceptible to simple hydrolysis under physiological pH conditions. Avoid strongly alkaline conditions (pH above 9) which can hydrolyse the lactam under prolonged exposure.
Reducing agents: PT-141 does not contain disulphide bonds and is not sensitive to reducing agents (DTT, BME, TCEP) — unlike Oxytocin Acetate. This makes PT-141 compatible with cell culture media containing reducing agents if required for other experimental components.
UV sensitivity: PT-141 contains a histidine residue (position 3 in its sequence) with a UV-absorbing imidazole ring, but this is not as photolabile as tryptophan. Standard laboratory lighting is not a significant stability concern for PT-141, though amber storage containers are recommended as a general precaution for all research peptides.
Solubility: PT-141 has good aqueous solubility at physiological pH. Reconstitute in bacteriostatic water at 1mg/mL as a stock solution. For assay dilutions below 10 nM, prepare fresh intermediate dilutions in the assay buffer rather than diluting directly from the 1mg/mL stock to avoid concentration errors at extreme dilutions.